Carcinogen-induced immunoreactivity to antinucleoside antibodies in HeLa cells.
D000099:Acetoxyacetylaminofluorene / Q000494:pharmacology; D000873:Anthracenes / Q000494:pharmacology; D000974:Antibodies, Antinuclear; D000937:Antigen-Antibody Reactions / Q000187:drug effects*; D001580:Benzopyrenes / Q000494:pharmacology; D002273:Carcinogens / Q000494:pharmacology*; D003513:Cycloheximide / Q000494:pharmacology; D003561:Cytarabine / Q000494:pharmacology; D004273:DNA, Neoplasm / Q000276:immunology; D003609:Dactinomycin / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005455:Fluorescent Antibody Technique; D006367:HeLa Cells; D006918:Hydroxyurea / Q000494:pharmacology; D008769:Methylnitronitrosoguanidine / Q000494:pharmacology*; D009363:Neoplasm Proteins / Q000096:biosynthesis; D011691:Puromycin / Q000494:pharmacology
D000873:Anthracenes; D000974:Antibodies, Antinuclear; D001580:Benzopyrenes; D002273:Carcinogens; D004273:DNA, Neoplasm; D009363:Neoplasm Proteins; D003561:Cytarabine; D008769:Methylnitronitrosoguanidine; D003609:Dactinomycin; D011691:Puromycin; D000099:Acetoxyacetylaminofluorene; D003513:Cycloheximide; D006918:Hydroxyurea